Tarceva is targeted anticancer drug that works by blocking a biological pathway referred to as the epidermal growth factor receptor (EGFR) pathway. The EGFR pathway is involved in cell growth and replication and when mutated or altered, excessive replication of cells can occur. Tarceva has been shown to improve treatment outcomes in selected patients with advanced non–small cell lung cancer or pancreatic cancer, and is also being evaluated in the treatment of other types of cancer. A recent phase II study suggested that it is effective with Nexavar for liver cancer. Tarceva alone is still in trials. Several have been completed and not reproted; one is ongoing: Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer, NCT00033462.
Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology [early online publication]. January 12, 2009.
Tarceva is targeted anticancer drug that works by blocking a biological pathway referred to as the epidermal growth factor receptor (EGFR) pathway. The EGFR pathway is involved in cell growth and replication and when mutated or altered, excessive replication of cells can occur. Tarceva has been shown to improve treatment outcomes in selected patients with advanced non–small cell lung cancer or pancreatic cancer, and is also being evaluated in the treatment of other types of cancer. A recent phase II study suggested that it is effective with Nexavar for liver cancer. Tarceva alone is still in trials. Several have been completed and not reproted; one is ongoing: Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer, NCT00033462.
Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology [early online publication]. January 12, 2009.